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Abstract      
PURPOSE: In this multi-center study, we evaluate for the first time the cumulative burden of morbidity 
(CBM) among over 1,200 testicular cancer survivors (TCS) and apply factor analysis to determine the 
co-occurrence of adverse health outcomes (AHOs).  
PATIENTS AND METHODS:  Participants were ≤55 years at diagnosis, finished first-line 
chemotherapy ≥1 year previously, completed a comprehensive questionnaire, and underwent physical 
examination. Treatment data were abstracted from medical records. A CBM score encompassed the 
number and severity of AHOs, with ordinal logistic regression used to assess associations with 
exposures. Nonlinear factor analysis and the nonparametric DETECT procedure determined which 
AHOs co-occurred.  
RESULTS: Among 1,214 TCS, approximately 20% had a CBM score of high (15%) or very high/severe 
(4.1%), while almost 80% scored medium (30%) or low/very low (47%). Increased risks of higher 
scores were associated with 4 cycles of either ifosfamide, etoposide, and cisplatin (VIPX4) (OR=1.96; 
95% CI 1.04-3.71) or bleomycin, etoposide, and cisplatin (BEPX4) (OR=1.44; 95% CI 1.04-1.98), older 
attained age (OR=1.18; 95%CI 1.10-1.26), current disability leave (OR=3.53; 95%CI 1.57-7.95), less-
than-college education (OR=1.44; 95%CI 1.11-1.87), and current or former smoking (OR=1.28; 95% CI 
1.02-1.63). CBM score did not differ following VIPX4 vs. BEPX4 (p=0.36). Asian race (OR=0.41; 95%CI 
0.23-0.72) and vigorous exercise (OR=0.68; 95%CI 0.52-0.89) were protective. Variable-clustering 
analyses identified six significant AHO clusters (chi-squareP<0.001): (1) hearing loss/damage, tinnitus 
(OR=16.3); (2) hyperlipidemia, hypertension, diabetes (OR=9.8); (3) neuropathy, pain, Raynaud 
phenomenon (OR=5.5); (4) cardiovascular and related conditions (OR=5.0); (5) thyroid disease, erectile 
dysfunction (OR=4.2); and (6) depression/anxiety, hypogonadism (OR=2.8).  
CONCLUSIONS: Factors associated with higher CBM may identify TCS in need of closer monitoring. If 
confirmed, identified AHO clusters could guide the development of survivorship care strategies. 
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Introduction 
 The number of cancer survivors has increased markedly in recent decades, with an estimated 
18 million in the U.S. by 2022.1 Given these increasing numbers, it is critical to understand and quantify 
the late effects of cancer and its treatment to inform survivorship care strategies. An important 
population in which to assess adverse health outcomes (AHOs) are survivors of testicular cancer (TC), 
the most common cancer in men age 18-39 years.2 Since effective cisplatin-based chemotherapy was 
introduced in the 1970s3, the overall age-adjusted 5-year relative survival rate is >95%,4 and survivors 
remain at risk for decades for the late effects of cancer and its treatment. Characterization of AHOs is 
facilitated by the homogeneity of treatment regimens. For four decades, therapy for advanced TC has 
typically consisted of platinum-based chemotherapy. For good-risk disease, standard treatment 
comprises either 3 cycles of bleomycin, etoposide, and cisplatin (BEPX3) or 4 cycles of etoposide plus 
cisplatin (EPX4), while for intermediate or poor-risk TC, 4 cycles of BEP (BEPX4) or 4 cycles of 
etoposide, ifosfamide, and cisplatin (VIPX4) are administered.5,6 Although treatment for good-risk TC 
with BEPX3 versus EPX4 results in lower cisplatin exposure, it is accompanied by potential bleomycin 
side effects.7 To our knowledge, no study to date has evaluated the cumulative burden of morbidity 
(CBM) after BEPX4 vs. VIPX4 or after BEPX3 vs. EPX4, taking into account both the number and 
severity of AHOs. Such characterization is important to develop risk-stratified, evidence-based follow-
up recommendations. Moreover, as noted previously,8 a better understanding of AHOs may help guide 
TC management, especially in the controversial area of whether good-risk patients should receive 
EPX4 or BEPX3.  
 To provide new information about CBM following contemporary cisplatin-based chemotherapy 
for TC, we examined both the number and severity of AHOs among 1,214 TC survivors (TCS) enrolled 
in the Platinum Study, a large, multi-center clinical investigation.9 We evaluated for the first time the co-
aggregation of AHOs to identify clusters that co-occur, and identified clinical, sociodemographic, and 
behavioral factors associated with elevated CBM.    
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Methods 
Study Population 
The Platinum Study was approved by each institutional IRB, and all participants provided written 
informed consent. The cohort was described in detail previously.2,10 Briefly, eligible TCS had 
histologic/serological diagnosis of germ cell tumor, were aged ≤55 years at diagnosis, completed first 
line cisplatin-based chemotherapy ≥1 year previously, and were undergoing routine follow-up at the 
participating site. All participants are referred to as TCS. At study enrollment, participants reported 
current prescription medication use with indication, underwent a brief physical examination, and 
completed comprehensive health questionnaires. Cancer diagnosis and treatment data were abstracted 
from medical records (see online Appendix-Supplemental Methods). TCS indicated the average time 
per week participating in various physical activities during the past year.11,12 These were grouped into 
vigorous (≥6 METs) and non-vigorous (<6 METS) activities (see online Appendix-Supplemental 
Methods).13 
 
Measurement of Adverse Health Outcomes 
Participant responses were mapped to individual AHOs and graded according to severity on a  
0-4 scale, using a modified version of the NCI Common Terminology Criteria for Adverse Events 
(CTCAEv4.03),14 as in prior studies.15,16 A multidisciplinary panel of experts agreed on all grades (DS, 
LBT, CF, HDS, LE, SDF). Supplementary Table 1 lists individual AHOs and grading criteria (see online 
Appendix-Supplemental Methods).15,16 If no response was provided (<1%), it was conservatively treated 
as no symptom/diagnosis. CBM score was calculated based on the number and severity of AHOs, 
following methods adapted from Geenen et al.15 (Supplementary Table 2). A secondary CBM score, 
CBMPt, was calculated using AHOs previously related to cisplatin exposure, i.e. peripheral sensory 
neuropathy, autonomic neuropathy, hearing damage, tinnitus, and kidney disease.17,18  
 
Statistical Analysis 
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Discrete and continuous data were described using numbers (percentages) and medians 
(ranges), respectively. Sociodemographic, health behavior, and treatment variables were individually 
tested for association with CBM score using student’s t-test (continuous variables) or Pearson’s chi-
square test (categorical variables). Variables were then combined in a multivariable ordinal logistic 
regression model with CBM score as the dependent variable. Unless otherwise noted, variables with 
Wald chi-square p-value ≥0.1 in the full model were removed from the final model. In the latter, very 
high and severe CBM categories were collapsed, given sparse data. Multivariable models that 
investigated the effect of cumulative cisplatin dose on CBMPt score included the same covariates as the 
main model except that chemotherapy regimen was omitted, given its strong correlation with cumulative 
cisplatin dose. 
 Ordinal logistic regression examined the relationship between CBM score and self-reported 
health (the dependent variable). For all ordinal logistic regression models, the assumption of 
proportionality of odds across response categories was confirmed by comparing the Bayesian 
Information Criterion (BIC) for the proportional odds model to the BIC from a partial proportional odds 
model. All descriptive statistics and regression analyses used Stata v14.1 (StataCorp.2015.College 
Station,TX). 
 Cluster analysis of variables was performed with non-linear factor analysis and the non-
parametric conditional item-pair covariance method of the cross-validated Dimensionality Evaluation To 
Enumerate Contributing Traits (DETECT) procedure (see online Appendix-Supplemental Methods). 
Each AHO was dichotomized: grades 0 and 1 were combined; and grades 2, 3 and 4 were combined. 
Due to sparse numbers, transient ischemic attack and stroke were collapsed into a single AHO; 
hypertriglyceridemia and hypercholesterolemia were combined into hyperlipidemia. Average item-pair 
odds ratios (OR) were calculated by averaging the log OR across AHO pairs, and then exponentiating 
the average value. 
 
Results 
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Median age at evaluation for 1,214 TCS was 37 years (range,18-74 years) and median time 
since chemotherapy completion was 4.2 years (range,1-30 years) (Table 1). Of all patients, 1,157 
(95.3%) were seen in clinic during routine follow-up care, and approximately 90% completed 
chemotherapy within 15 years of enrollment. Most participants (N=1,035; 85.3%) received BEPX3 
(N=460; 37.9%), BEPX4 (N=222; 18.3%), or EPX4 (N=353; 29.1%); 44 TCS received VIP, typically 4 
cycles (n=32). Median cumulative cisplatin dose was 400mg/m2, with approximately one third receiving 
300mg/m2 (N=447; 36.8%). Retroperitoneal lymph node dissection (RPLND) was performed on 46.3% 
participants. Most TCS were white (85.3%), married/living as married (61.0%), employed (88.7%), and 
educated beyond high school (88.3%). 
 The most prevalent AHOs, of any severity, were obesity (41.7% grade 2; 26.0% grade 3; 3.9% 
grade 4), sensory neuropathy (28.3% grade 1; 14.5% grade 2; 13.4% grade 3), tinnitus (25.0% grade 1; 
7.1% grade 2; 7.5% grade 3), and hearing damage (24.5% grade 1; 13.5% grade 2; 1.2% grade 3) 
(Table 2). Raynaud phenomenon occurred in approximately 33% of TCS (15.6% grade 1, 8.7% grade 
2, 9.1% grade 3), and pain in about 25% (13.6% grade 1, 9.8% grade 2, and 1.5% grade 3). 
Hypogonadism (10.2% grade 2) and erectile dysfunction (15.9% grade 1, 12.5% grade 2) were also 
observed. 
 Figure 1 depicts the CBM score. Approximately 20% TCS had a score of high (N=180; 14.8%), 
very high (N=46; 3.8%) or severe (N=1; 0.1%), whereas 76% had a score of very low, low, or medium 
(N=104; 8.6%, N=458; 37.7% and N=360; 29.7%, respectively). Only 5.4% of TCS had no AHOs. All 47 
participants with a very high or severe score had grade 4 obesity.  
 Bivariate associations of clinical, sociodemographic, and health behavior factors with CBM 
score are shown in Supplemental Table 3. In a multivariable model (Table 3) controlling for time since 
chemotherapy and enrollment center, the following were significantly associated with higher CBM 
score: older attained age (OR=1.18 per 5 years), BEPX4 (OR=1.44 versus BEPX3), VIPX4 (OR=1.96 
versus BEPX3), below college-level education (OR=1.44), current disability leave (OR=3.53), and 
former or current smoking status (OR=1.28). Although the OR for VIPX4 was slightly higher than that 
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for BEPX4, the difference was not significant (p=0.36). Disease stage was not associated with CBM 
score (p=0.48), suggesting that increased scores after BEPX4 or VIPX4 were not explained by more 
advanced tumor status. CBM scores after EPX4 and BEPX3 were similar (p=0.65). No significant 
differences were observed for individual AHOs except Raynaud phenomenon (P<0.001), for which 
prevalence and severity after BEPX3 (n=183 patients (39.8%): 18.5% grade 1, 10.4% grade 2, and 
10.9% grade 3) exceeded EPX4 (n=84 patients (23.8%): 12.2% grade 1, 16.8% grade 2, and 4.8% 
grade 3).  
Asian race (OR=0.41) and vigorous exercise (OR=0.68) were inversely associated with higher 
CBM score. Lower risk in Asian TCS reflects the fact that fewer patients had higher severity grades for 
15 of 22 AHOs vs. whites (e.g., peripheral sensory neuropathy: grade 3 [8.5% vs. 13.5%]; hearing loss: 
grade 2 [8.5% vs. 14.1%], grade 3 [0% vs. 1.2%]). Similar trends were observed for autonomic 
neuropathy, tinnitus, Raynaud phenomenon, pain, kidney disease, hypertension, CAD, peripheral artery 
disease, obesity, thyroid disease, depression/anxiety, erectile dysfunction, and hypogonadism. 
 The relationship between cumulative cisplatin dose and overall CBM score was of borderline 
significance (OR per 100 mg/m2=1.16; 95%CI 0.99-1.37; p=0.064) in the multivariable model. However, 
when limited to conditions previously attributed to cisplatin,14,15 each 100 mg/m2 increase in cumulative 
dose was associated with significantly worse CBMPt (OR per 100mg/m
2=1.34; 95%CI, 1.14-1.58; 
p<0.001). 
 Increasing CBM score was significantly associated with worse self-reported health. Compared 
to patients with a score of none, the risk of worse self-reported health among those scored as very low, 
low, medium, high, or very high/severe was 1.94 (95%CI 1.08-3.48), 2.82 (95%CI 1.72-4.62), 5.91 
(95%CI 3.56-9.81), 10.90 (95%CI 6.28-18.93), and 34.17 (95%CI 16.54-70.62), respectively.  
 Results from both variable-clustering methods converged in the analysis of AHOs to yield six 
major groups of signs/symptoms (chi-square for model fit: P<0.001) with pairwise ORs for given 
clusters as follows: (1) hearing loss/damage, tinnitus (OR=16.3); (2) metabolic disorders (diabetes, 
hypertension, hyperlipidemia) (OR=9.8); (3) neuropathy and related conditions (sensory neuropathy, 
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autonomic neuropathy, pain, Raynaud phenomenon) (OR=5.5); (4) cardiovascular disease (CVD) and 
related conditions (CAD, stroke, kidney disease, peripheral artery disease, thromboembolism, and 
obesity) (OR=5.0); (5) erectile dysfunction (ED) and thyroid disease (OR=4.2); and (6) hypogonadism 
and depression/anxiety (OR=2.8). Clusters (1) and (3), although distinct, were strongly correlated 
(r=0.658; p<0.001), as were clusters (5) and (6) (r=0.914; p<0.001). 
 
Discussion 
 Our results are based on the largest study to date of TCS given contemporary cisplatin-based 
chemotherapy. For the first time, to our knowledge, we characterize the CBM, showing that even at a 
young age almost one in five patients had a score of high to severe, with only 5% reporting no AHOs. 
Although CBM was higher in TCS given BEPX4 or VIPX4 (vs. BEPX3), scores did not differ significantly 
between these two regimens (p=0.36). Neither did CBM differ between BEPX3 and EPX4, the standard 
approaches for good risk disease. The higher prevalence and severity of Raynaud phenomenon after 
BEPX3 is consistent with the known relationship with bleomycin,7 although it may also be related to 
cisplatin.19 Increasing cumulative cisplatin dose significantly increased risk for a higher CBM score for 
AHOs related to neuropathy, ototoxicity and kidney disease. The strong association between higher 
CBM score and worse self-reported health indicates that the score reflects a health status perceptible 
to patients. These and other new findings are discussed below. 
 Previous U.S. investigations of TCS2,20-24 have been limited in scope, generally either not 
addressing AHOs21,23,24 or evaluating less than five conditions22 (Supplemental Table 4). Although 
three studies obtained treatment information from medical records, only Oh et al.22 (N=143 patients) 
examined AHOs (n=4) by therapy. Hashibe et al.20 evaluated AHOs through linkage with ICD-9 codes, 
but results were not presented by treatment, and only 168 patients received chemotherapy (type 
unspecified). In contrast, we evaluated a wide spectrum of AHOs by type and severity among >1,200 
TCS with detailed treatment information. The resultant CBM score comprises a range of AHOs likely 
related to TC and its treatment, and also to long-term platinum retention. After chemotherapy 
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completion, circulating serum platinum remains measurable at levels up to 1,000 times above normal 
for 20 years.25 Ongoing endothelial cell and vascular damage26 occur for many years, and long-term 
serum platinum levels have been significantly related to neuropathy,27 hypertension,28 and 
hypercholesterolemia.28 
 Since TC occurs largely in white males,29 data on Asian patients are sparse. Decreased risks of 
a higher CBM score in Asian vs. white TCS largely reflected the lower occurrence of high severity 
grades in Asians for most AHOs. These included known treatment-related toxicities, possibly reflecting 
differences in drug absorption, distribution, metabolism and excretion, but also others. Although we 
adjusted for sociodemographic and health behavior factors, it is possible that other unmeasured 
influences may have accounted for this finding, which remains to be confirmed.  
 It is noteworthy that although the CBM score was slightly higher after VIPX4 than after BEPX4, 
the difference was not significant (p=0.36). Both are standard chemotherapy for intermediate and poor-
risk disease,5,6 showing equivalent survival. Although an early, randomized trial showed that VIPX4 was 
associated with greater acute toxicity than BEPX4,30 no study has subsequently addressed long-term 
AHOs, as done here. Additional follow-up, as planned for this unique cohort, will be required to further 
quantify the CBM associated with each regimen. CBM was also similar for BEPX3 vs. EPX4, the two 
commonly applied regimens for good-risk disease. In a curable disease such as TC with long life 
expectancy and equivalent therapy options, the availability of AHO data becomes increasingly 
important to inform treatment decisions.8  
 The striking association between CBM score and self-reported health indicates that the score 
captures outcomes that impact patients’ self-perception of health. The risk of worse self-reported health 
among patients with very high/severe CBM scores rose to over 30-fold compared to those with a score 
of none. These results further underscore the need to assess outcomes that impact self-perceived 
health, as these can guide the development of survivorship care strategies that are valued by patients. 
To our knowledge, this is the first variable-based factor analysis of AHOs in long-term cancer 
survivors. Prior analyses have largely been conducted in patients either during cancer treatment,31,32 
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shortly after therapy completion,33,34 or during palliative/hospice care.35 Only Kim et al.36 evaluated 
patients who were either 2-5 years (N=66) or >5 years (N=56) post-cancer diagnosis, although some 
were still undergoing treatment. Factor analysis provides insights into groups of conditions that may co-
occur and perhaps share etiology. For example, hearing loss and tinnitus reflect known cisplatin-
associated damage to the auditory system.10,37 Associations between neuropathy and Raynaud’s 
phenomenon have been reported in non-chemotherapy exposed individuals,38,39 although the biologic 
basis is incompletely understood and co-occurrence could reflect symptom cross-reporting. Pain is 
frequently associated with chemotherapy-induced peripheral neuropathy, with no agents currently 
available for prevention or treatment.40  
 The cluster of hyperlipidemia, hypertension, and diabetes present at time of clinical evaluation 
represents components of the metabolic syndrome (MetS),41 consistent with studies reporting 
increased MetS risk among European TCS.42-45 The co-occurrence of AHOs related to CVD supports 
European investigations that show a 1.4-to-7-fold higher CVD risk among cisplatin-treated TCS vs. 
either the general population or patients managed with surgery alone.26,46-49 Presentation with one or 
more of these AHOs suggests closer screening for other cluster-related conditions that could signal 
elevated risk for CVD morbidity and mortality.7 Hypogonadism and depression, respectively, represent 
a biologic consequence of TC treatment50,51 and possible associated psychological outcome. A 
potential relationship between hypogonadism and depression in the general population has been 
recognized, with other symptoms including muscle weakness and loss of energy.52-56  
An association of ED and thyroid disease has not been previously shown in TCS, as it has in 
non-cancer populations.57-63 Of 39 TCS with thyroid disease, 33 and 6 reported hypothyroidism and 
hyperthyroidism, respectively. Although associations of hypothyroidism57,62,63 and hyperthyroidism57,61-63 
with ED were observed in several studies in non-cancer populations, a relationship with hypothyroidism 
was not confirmed in the largest investigation to date,61 possibly due to the low prevalence, and 
requires further investigation.  
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 The strong association between vigorous physical activity and lower CBM score, as well as with 
a reduced absolute number of AHOs in prior analyses,2 can inform future intervention strategies. 
Studies of childhood cancer survivors have shown that exercise reduces the risk of late effects such as 
CVD,64 and the same likely applies to TCS. The apparent inverse relation between increased risk of a 
high CBM score and follow-up time is due to the disproportionate contribution of early-onset toxicities 
(e.g., neuropathy, tinnitus), which are more prevalent than later-onset toxicities (e.g., 
hypercholesterolemia, hypertension), reflecting the relatively short median follow-up time and young 
cohort age.   
A major strength of this study is the estimation of both the number and severity of AHOs in the 
largest TCS cohort to date treated primarily with EPX4, BEPX3, BEPX4 or VIPX4. Other strengths 
include the high participation rate (93%), detailed medical chart abstraction, and estimation of risk 
without the confounding effect of radiotherapy. An inherent limitation to all cross-sectional studies is the 
inability to assess causality between clinical, sociodemographic and health behavior characteristics and 
CBM score. AHOs were largely self-reported without baseline data, similar to previous TCS 
studies.21,23,65 As in Geenen et al.,15 a limitation is that we could not compare the CBM score to that of a 
normative population, given the unavailability of data. Equivalent weight was assigned to all AHOs, 
whereas TCS may weigh these differently; some AHOs capture symptoms that can markedly affect 
TCS (e.g. neuropathy) whereas others encompass conditions treated by medications that may be less 
bothersome (e.g. hypertension). Further studies are needed to investigate the impact of specific AHOs 
on health-related quality of life in this under-studied population. 
 In conclusion, at a median follow-up of only 4.2 years, almost 1 in 5 TCS have a CBM score of 
high, very high, or severe. Importantly, no difference in CBM score was observed among TCS receiving 
BEPX4 vs. VIPX4, or among those given EPX4 vs. BEPX3, although it will be important to monitor 
patients long-term. The value of variable-clustering analysis in revealing the co-occurrence of AHOs is 
underscored by our findings, and should be considered for other groups of long-term cancer survivors 
to highlight potential areas of research into mechanistic bases of toxicities. Ongoing genetic research in 
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our cohort has already begun to characterize biologic pathways underlying cisplatin-related 
toxicities66,67 and can identify new research opportunities aimed at developing agents to prevent, 
mitigate and treat adverse sequelae, not only among TCS, but other survivors after cisplatin-based 
chemotherapy. In the interim, if confirmed, our results could inform survivorship care strategies and 
assist health care providers in identifying conditions, or groups of conditions, for which to screen, 
counsel, and treat TCS. 
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Table 1. Clinical, Sociodemographic and Health Behavior Characteristics of 1,214 Survivors of 
Cisplatin-Treated Germ Cell Tumors (GCT)  
Clinical Characteristic, number (%) 
Age at GCT diagnosis, years
a
 
Median [range] 
< 20  
20 to 29  
30 to 39  
≥ 40 
 
30 [15 - 60] 
89 (7.3) 
482 (39.7) 
403 (33.2) 
232 (19.2) 
Age at evaluation, years 
Median [range] 
<20  
20 to 29  
30 to 39  
40 to 49  
50 to 59  
60 to 69  
 
37 [18 - 74] 
9 (0.7) 
265 (21.8) 
436 (35.9) 
314 (25.9) 
164 (13.5) 
26 (2.1) 
Calendar year of diagnosis
b
 
Before 2000 
2000-2004 
2005-2009 
2010-2016 
 
146 (12.0) 
145 (11.9) 
317 (26.1) 
598 (49.3) 
Histological type of GCT 
Seminoma 
Non-seminoma 
GCT, NOS 
 
310 (25.5) 
885 (72.9) 
19 (1.6) 
GCT site
c
 
Testis 
Extragonadal 
 
1069 (88.1) 
135 (11.1)  
Type of cisplatin-based chemotherapy
d
 
BEP 
≤ 2 cycles 
3 cycles 
4 cycles 
≥ 5 cycles 
EP 
≤ 3 cycles 
4 cycles 
≥ 5 cycles 
VIP 
3 cycles 
4 cycles 
≥ 5 cycles 
Other
e
 
≤ 2 cycles 
3 cycles 
4 cycles 
≥ 5 cycles 
 
710 (58.5) 
21 
460 
222 
7 
388 (32.0) 
23 
353 
12 
44 (3.6) 
4 
32 
8 
69 (5.7) 
11 
8 
41 
9 
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Cumulative dose of cisplatin (mg/m
2
)
f
 
Median [range] 
< 300 
300 
301-399 
400 
> 400 
 
400 [100 - 828] 
61 (4.9) 
447 (36.8) 
44 (3.2) 
589 (48.5) 
55 (4.4) 
Clinical Characteristic, number (%)  
Retroperitoneal lymph node dissection (RPLND)
g
 
Yes 
No 
 
562 (46.3) 
639 (52.6) 
Time since completion of chemotherapy (years)
h
 
Median [range] 
< 2  
2 to 5  
6 to 9  
≥ 10 
 
4.2 [1 - 30] 
329 (27.1) 
423 (34.8) 
186 (15.3) 
261 (21.5) 
Sociodemographic characteristic, number (%) 
Race
i
 
White 
African American 
Asian 
Other 
 
1,036 (85.3) 
16 (1.3) 
59 (4.9) 
68 (5.6) 
Marital status
j
 
Single or never married 
Married/living as married 
Widowed/divorced/separated 
 
389 (32.0) 
740 (61.0) 
70 (5.8) 
Education
k
 
High school or less 
After high school but not college graduate 
College or university graduate 
Post-graduate 
 
139 (11.5) 
289 (23.8) 
508 (41.9) 
275 (22.7) 
Current employment status
l
 
Unemployed 
Employed 
Retired 
On disability leave 
 
74 (6.1) 
1,077 (88.7) 
15 (1.2) 
30 (2.5) 
Health behavior, number (%) 
Smoking status
m
 
Never 
Former 
Current 
 
714 (58.8) 
392 (32.3) 
107 (8.8) 
Average number of alcoholic drinks in past year
n
 
Rarely or never 
1 to 3 per month 
1 to 6 per week 
≥ 1 daily 
 
239 (19.7) 
180 (14.8) 
569 (46.9) 
218 (18.0) 
Engage in vigorous physical activity (≥6 METs)
o
 
Yes 
No 
 
835 (68.8) 
378 (31.1) 
Abbreviations: BEP, bleomycin, etoposide, cisplatin; EP, etoposide, cisplatin; GCT, germ cell tumor; MET, 
metabolic equivalent task; NOS, not otherwise specified; RPLND, retroperitoneal lymph node dissection; VIP, 
etoposide, ifosfamide, cisplatin. 
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a
 Age at diagnosis was not available for 8 individuals. 
b
 Year of GCT diagnosis was not available for 8 individuals. 
c
 GCT site was not available for 10 individuals. 
d
 Of the 52 patients given VIPX4, 44% had mediastinal disease whereas 47% had disease confined to the testis, 
and in the remainder (9%), other extra-gonadal sites were involved. This is in contrast to the smaller percentage 
of patients with mediastinal disease (i.e. 7.2% or less) in the other treatment groups. 
e
 Other chemotherapy regimens included cisplatin and ifosfamide (N=25); cisplatin, vinblastine, and bleomycin 
(N=6); ifosfamide, bleomycin, cisplatin, and etoposide (N=6); and other cisplatin-based regimens (N=32). Number 
of cycles was not available for 4 individuals who received a chemotherapy regimen designated ‘Other’. 
f
 Cumulative dose of cisplatin was not available for 18 individuals. 
g
 RPLND status was not available for 13 individuals. 
h
 Time since completion of chemotherapy was not available for 15 individuals. 
i
 Race was not stated for 19 individuals. 
j
 Marital status was not stated for 15 individuals. 
k
 Education status was not stated for 3 individuals. 
l
 Employment status was not stated for 18 individuals. 
m
 Smoking status was not stated for 1 individual. 
n
 Alcohol consumption was not stated for 8 individuals. 
o
 Exercise was assessed in this study using a validated questionnaire
11,12
 that asks participants to report their 
average time per week (over the past year) spent at each of nine recreational activities: walking or hiking 
(including walking to work); jogging (slower than 10 minute miles); running (10 minute miles or faster); bicycling 
(including stationary bike); aerobic exercise or dance/exercise machines; lower intensity 
exercise/yoga/stretching/toning; tennis, squash or racquetball; lap swimming; and weight lifting/strength training. 
Each physical activity was assigned a metabolic equivalent (MET) value. MET values are a commonly used 
metric for describing the relative energy expenditure of a specific type of physical activity (1 MET=1 kcal/kg/hour, 
or the energy cost of sitting quietly). The MET values for each activity were then used to calculate MET-
hours/week for each participant, and these were grouped into categories of vigorous or non-vigorous physical 
activity following standard definitions.
13
 Physical activity was not stated for 1 individual. 
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Table 2. Prevalence of Adverse Health Outcome (AHO) By Severity Grade, N (%) 
 
AHO: all 
grades Grade 1 Grade 2 Grade 3 Grade 4 
Peripheral sensory neuropathy
a
 683 (56.3) 344 (28.3) 176 (14.5) 163 (13.4) NA
b
 
Autonomic neuropathy
c,d
 323 (26.6) 234 (19.3) 68 (5.6) 21 (1.7) NA 
Hearing damage
c
 476 (39.2) 297 (24.5) 164 (13.5) 15 (1.2) 0 
Tinnitus
c
 481 (39.6) 304 (25.0) 86 (7.1) 91 (7.5) NA 
Raynaud phenomenon
c
 405 (33.4) 189 (15.6) 105 (8.7) 111 (9.1) NA 
Pain
a
 302 (24.9) 165 (13.6) 119 (9.8) 18 (1.5) NA 
Kidney disease
a
 30 (2.5) 27 (2.2) 3 (0.3) NA NA 
Hypercholesterolemia
a
 96 (7.9) NA 96 (7.9) NA NA 
Hypertriglyceridemia
a
 6 (0.5) NA 6 (0.5) NA NA 
Hypertension
a
 114 (9.4) NA 114 (9.4) NA NA 
Diabetes
a
 37 (3.0) NA 20 (1.7) 17 (1.4) NA 
Coronary artery disease
a
 20 (1.6) 4 (0.3) 7 (0.6) 9 (0.7) NA 
Transient ischemic attack
c
 8 (0.7) 8 (0.7) NA NA NA 
Stroke
c
 6 (0.5) NA 6 (0.5) NA 0 
Peripheral artery disease
a
 56 (4.6) 27 (2.2) 14 (1.2) 15 (1.2) NA 
Thromboembolic event
a
 88 (7.2) NA 44 (3.6) 44 (3.6) NA 
Obesity
e
 868 (71.5) NA
f
 506 (41.7) 315 (26.0) 47 (3.9) 
Thyroid disease
a
 39 (3.2) 20 (1.7) 19 (1.6) NA NA 
Anxiety and/or depression
g
 75 (6.2) NA 75 (6.2) NA NA 
Erectile dysfunction
a
 345 (28.4) 193 (15.9) 152 (12.5) NA NA 
Hypogonadism
g
 124 (10.2) NA 124 (10.2) NA NA 
a 
Based on patient reported outcomes and prescription medication use. 
b 
NA, not applicable, as data needed to assign these  toxicities according to the CTCAE definitions were not captured in the 
present study.
 
c
 Based on patient reported outcomes
 
d
 Among participants with grade 0, grade 1, grade 2, and grade 3 autonomic neuropathy, 22, 7, 2, and 1, respectively, reported 
taking a beta-blocker. 
e
 Calculated using weight and height assessments from physical exam conducted at clinical evaluation. 
f
 CTCAE does not include a grade 1 for obesity 
g
 Based on prescription medication use.  
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Table 3. Multivariable Ordinal Logistic Regressiona of Factors Associated With CBM 
Score  
 Odds Ratio (95% CI) p-value 
Age at evaluation (per 5 years)
b
 1.18 (1.10, 1.26) <0.001 
Time since chemotherapy completion, years 
   < 2  
   2-5  
   6-9  
   10+  
 
Ref. 
0.91 (0.68, 1.23) 
0.61 (0.42, 0.89) 
0.55 (0.38, 0.85) 
 
- 
0.54 
0.010 
0.002 
Race 
   White 
   Black/African-American 
   Asian 
   Other 
 
Ref. 
1.56 (0.49, 5.03) 
0.41 (0.23, 0.72) 
1.05 (0.63, 1.76) 
 
- 
0.45 
0.002 
0.84 
Education 
   College or post-college graduate 
   Less than college education 
 
Ref. 
1.44 (1.11, 1.87) 
 
- 
0.006 
Current employment status 
   Employed 
   Unemployed 
   Retired  
   On disability leave 
 
Ref. 
0.90 (0.55, 1.47) 
1.10 (0.36, 3.39) 
3.53 (1.57, 7.95) 
 
- 
0.66 
0.87 
0.002 
Smoking status 
   Never 
   Current or Former 
 
Ref. 
1.28 (1.02, 1.63) 
 
- 
0.037 
Vigorous physical activity (≥6 METs)
c
 
   No 
   Yes
 
 
Ref. 
0.68 (0.52, 0.89) 
 
- 
0.004 
RPLND
d
 
   No 
   Yes 
 
Ref. 
0.88 (0.69, 1.12) 
 
- 
0.31 
Type of chemotherapy
e
 
   BEPX3 
   EPX4 
   BEPX4 
   VIPX4 
 
Ref. 
1.09 (0.75, 1.60) 
1.44 (1.04, 1.98) 
1.96 (1.04, 3.71) 
 
- 
0.65 
0.028 
0.039 
Abbreviations: BEP, bleomycin, etoposide, cisplatin; EP, etoposide, cisplatin; MET, metabolic equivalent task; 
RPLND, retroperitoneal lymph node dissection; VIP, etoposide, ifosfamide, cisplatin 
a
 Odds ratios and p-values are from an adjusted model that includes all other variables listed in the table, as well as 
enrollment center, with CBM score as the outcome (dependent) variable. The ‘very high’ and ‘severe’ categories were 
collapsed due to sparse data. Analysis includes 1,013 (83.4%) testicular cancer survivors with non-missing data for 
all variables in the model. 
b
 Age at diagnosis was not included in the model given the strong correlation with age at evaluation (r=0.81), which 
was included
 
c
 See Table 1, footnote o and Appendix-Supplemental Methods for details on assessment of physical activity. 
d 
RPLND was retained in the multivariable model to control for potential residual confounding, given its correlation 
with chemotherapy regimen (P < 0.001); approximately 34%, 55%, 66%, and 44% of TCS treated with BEPX3, EPX4, 
BEPX4, and VIPX4, respectively, had an RPLND. 
e
 Disease stage was not significantly associated with CBM score (P = 0.48) , suggesting that increased scores after 
BEPX4 or VIPX4 were not explained by more advanced tumor status
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Figure 1. Distribution of Cumulative Burden of Morbidity (CBM) Score Among 1,214 
Participants in the Platinum Study. 
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